These findings suggest that B2M levels in plasma might serve as an indicator for distinguishing CNS lymphoma from other types of intracranial tumors and non-CNS lymphoma, and predicting patient outcomes in CNS lymphoma. The gene discussed is B2M; the disease is primary central nervous system lymphoma.